# Myriad Genetics Raises 2026 Revenue Outlook Midpoint to $785 Million By John Kim Canonical URL: https://www.tokenpost.com/news/business/50501 Published: 2026-11-07T02:04:37.000Z Updated: 2026-11-07T02:04:37.000Z Section: Business > The company set a range of $780 million to $790 million as higher revenue per test partly offsets expected Prenatal Health softness. Myriad Genetics raised the midpoint of its 2026 revenue outlook to $785 million, setting a range of $780 million to $790 million as higher revenue per test partly offsets expected Prenatal Health softness. Myriad management attributed reimbursement pressure to increased zero-pay outcomes and denials, rather than lower contract rates or changes in medical policy. The company identified process improvements, AI-enabled workflows and payer-specific market access efforts as ways to address the pressure. The outlook update follows Myriad’s [agreement to sell its Prenatal Health testing business to Labcorp](). For the period after the planned sale, management expects revenue growth to improve by more than 1 percentage point and gross margin by more than 5 percentage points. Myriad also expects meaningful progress in bottom-line profitability in 2027. ## Links in this article - [agreement to sell its Prenatal Health testing business to Labcorp](https://www.tokenpost.com/news/business/36029)